The Europe Colorectal Cancer Market was worth $3.28 billion in 2018 and estimated to be growing at a CAGR of 2.45%, to reach $3.7 billion by 2023. Colorectal cancer is a consequence of unrestrained cell growth that occurs in the appendix, colon, and the rectum region. Some of the generally seen symptoms of colorectal cancer are blood in the stool, weight loss, fatigue, and irregular bowel movements.
Colorectal cancer is identified with a biopsy, which then followed by medical imaging to know its extent. Depending on the stage and how much the cancer has expanded, a combination of radiation therapy, chemotherapy, and targeted therapy is recommended by most oncologists.
Rise in pipeline colorectal cancer screening tests is one of the major driver for the colorectal cancer market in this region. Another aspect is that European countries face comparable economic and demographic burdens and share an interest in scrutinizing their impact on health outcomes nationally and across Europe. However, high cost of treatment is one of the main factors hindering the growth of this market.
The Europe Colorectal Cancer Market is segmented based on Diagnosis and Treatment. The market for Colorectal Cancer, on the basis of Diagnosis is segmented into Digital Rectal Examination, Faecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, Virtual Colonoscopy. On the basis of Treatment, the global Colorectal Cancer market is segmented into Surgery and Radiation Therapy, Chemotherapy, Targeted Therapies, Resistance to Pharmacological Therapies.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. European is the third largest market with a global share of 24%. Germany is the largest market share holder for the colorectal Cancer market in this region, followed by the UK and France. Other significant markets in the region are Norway, Netherlands, Denmark, and Greece.
The major companies dominating the market in this region are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, Hoffmann La Roche, Debiopharm Group, Vaccinogen BD.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Diagnosis
5.1.1 Digital Rectal Examination
5.1.2 Faecal Occult Blood Test
5.1.3 Flexible Sigmoidoscopy
5.1.4 Colonoscopy
5.1.5 Virtual Colonoscopy
5.2 By Treatment
5.2.1 Surgery and Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Targeted Therapies
5.2.4 Resistance to Pharmacological Therapies
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Diagnostics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Alere
8.3 Beckman Coulter
8.4 Clinical Genomics
8.5 Companion Dx
8.6 Hoffmann La Roche
8.7 Debiopharm Group
8.8 Vaccinogen BD
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
